Sponsors (3)
The bill formalizes and funds multi-stakeholder consensus-building and transparency for rare-disease development—potentially speeding and clarifying treatment pathways for patients—while adding administrative burdens to FDA, raising conflict-of-interest concerns, and relying on modest funding that may limit its effectiveness.
Patients with rare diseases may get clearer, faster development paths for treatments because multi-stakeholder consensus on trial designs, endpoints, and biomarkers will be produced and shared.
Patients, researchers, and the public gain more transparency because meeting transcripts, recordings, and summaries highlighting consensus and next steps must be published within 180 days.
Researchers, developers, and small businesses get clearer regulatory expectations through a standing steering committee (FDA, academics, patients, industry) that sets topics and processes, improving predictability for product development.
Patients, hospitals, and researchers could face slower FDA review or diverted staff time because review divisions will have increased administrative workload to attend meetings and produce follow-up reports.
Patients and smaller developers risk perceived or actual bias because industry participation in the steering committee and meetings could create conflicts of interest or favor industry-friendly pathways.
Small businesses and researchers may find public summaries less useful if commercially sensitive or trade-secret technical details are omitted, limiting practical benefit to sponsors.
Based on analysis of 2 sections of legislative text.
Requires FDA, via the Reagan‑Udall Foundation, to convene externally led, science‑focused meetings to align stakeholders on scientific approaches for rare disease drug development and to publish meeting outputs.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to establish a process for externally led, science-focused drug development meetings, and for other purposes.
Introduced February 24, 2025 by Doris Matsui · Last progress February 24, 2025
Creates a formal process for externally led, science-focused drug development (EL–SFDD) meetings to bring together FDA staff, outside experts, patient groups, scientific organizations, and drug developers to address scientific challenges in developing therapies for rare diseases. It directs the Secretary of HHS (through FDA) to arrange with the Reagan‑Udall Foundation to convene at least four focused meetings per year, and requires a permanent multistakeholder steering committee to set meeting topics, objectives, and participant rules. Each meeting must have published objectives, agendas, participation rules, and a public report summarizing discussions and recommendations to inform drug development approaches (trial design, endpoints, biomarkers, natural history use, manufacturing). The Foundation must follow conflict-of-interest rules and include FDA representatives, academic experts, patient representatives, and industry in the steering committee.